ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

Animal Diagnostic Lab concept OK’d

February 18, 1994

Rauscher To Become ACS VP For Research Nov. 1; Search Starts for New NCI Director

September 24, 1976

NCAB, President’s Cancer Panel honor the late Paul Calabresi.

June 11, 2004

House Measure Would Eliminate AHRQ, Rescind PCORI, Cut Outcomes Research, And Halt NIH’s Title 42 Hiring Program

July 20, 2012

Politics, Short Tempers, Grievances Dominate NIH Panel On Unconventional Medical Practices

September 25, 1992

In Brief: Balch To Head City of Hope; Rowinsky Moves To San Antonio; Klausner’s Deputy Joins NCI

August 9, 1996